COMP <GO>
ADRX vs BRVE // EV/EBITDA & P/E VALUATION
ADARx Pharmaceuticals Inc. (NASDAQ) VS. Braveheart Bio Inc. (NASDAQ) • 15-METRIC TALLY: ADRX 0
— BRVE 2
■ METRIC PARITY
LAST: $17.85 (-0.56%) • MKT CAP: $1.91B
valuation
—
LAST: $21.19 (-2.62%) • MKT CAP: $1.91B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADRX VS. BRVE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADRX | BRVE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.8 | 49.2 | -12.36 | BRVE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.91B | $1.91B | -$1.5M | BRVE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADRX REV | BRVE REV | ADRX GROSS % | BRVE GROSS % | ADRX FCF | BRVE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADRX // BETA —
BRVE // BETA —